Heterogeneous treatments reflect the changing landscape and availability of new treatments, as well as the high unmet medical need in older, METex14 patients who had more advanced disease at diagnosis. MET-targeted therapies could be beneficial in patients with these rare MET alterations. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2021.06.015
Authors: Marisa Bittonia James Chih-Hsin Yang, Jin-Yuan Shih, Nir Peled, Egbert F. Smite, D. Ross Camidge, Rajeswara Rao Arasada, Dina Okseng, Emmanuelle Boutmy, Christopher Stroh, Andreas Johne, David P. Carbonea and Paul K. Paik
Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a subset of patients with actionable mutations, targeted therapy continues to provide durable responses. Advances in molecular and immunohistochemical techniques have made it possible to usher lung cancer into the era of personalized medicine, with the patient getting individualized treatment based on these markers. This review summarizes the recent advances in advanced NSCLC targeted therapy, focusing on first-in-human and early phase I/II clinical trials in patients with advanced disease. We have divided our discussion into different topics based on these agents' mechanisms of action. This article is aimed to be the most current review of available and upcoming targeted NSCLC treatment options. We will also summarize the currently available phase I/II clinical trial for NSCLC patient..... READ ARTICLE
Journal of Hematology & Oncology DOI:10.1186/s13045-021-01121-2
Authors: Umair Majeed, Rami Manochakian, Yujie Zhao & Yanyan Lou
Among patients with advanced EGFR- and ALK-positive NSCLC, higher TKI Out-Of-Pocket costs are associated with decreased TKI adherence, a higher likelihood of TKI discontinuation, and inferior survival. READ ARTICLE
Journal of Clinical Oncology: Oncology Practice DOI: 10.1200/OP.20.00692 JCO
Authors: Bernardo H.L. Goulart, Joseph M. Unger, Shasank Chennupati, Catherine R. Fedorenko, Scott D. Ramsey
Read More